Neuland accelerates peptide manufacturing expansion to meet rising customer demand
<div id="mail-editor-reference-message-container" dir="auto" style="caret-color:#212121;color:#212121;font-family:Aptos;font-size:16px;"><div id="mail-editor-reference-message-body" dir="auto"><div id="mail-editor-reference-message-container"><div id="mail-editor-reference-message-body" dir="auto"><div id="mail-editor-reference-message-container"><div id="mail-editor-reference-message-body"><div id="mail-editor-reference-message-container"><div id="mail-editor-reference-message-body" dir="auto"><div id="ms-outlook-mobile-signature" dir="ltr"><div style="direction:ltr;text-align:center;background-color:white;margin:0cm;font-family:Arial, sans-serif;font-size:14pt;color:black;"><strong><br />First commercial peptide manufacturing module now operational, with additional capacity expansion underway</strong></div><div style="direction:ltr;text-align:justify;margin:0cm;font-family:Arial, sans-serif;font-size:11pt;color:#373737;"><span style="background-color:white;"><strong></strong></span></div><div style="direction:ltr;text-align:justify;margin:0cm;font-family:Arial, sans-serif;"><span style="font-size:11pt;color:#373737;background-color:white;"><strong>Hyderabad, India,</strong></span><span style="font-size:11pt;color:black;background-color:white;"><strong>Sep</strong></span><span style="font-size:11pt;color:#373737;background-color:white;"><strong>16, 2026</strong>:<span> </span></span><span style="font-size:12pt;color:black;">:<span> </span></span><span style="font-size:11pt;color:#96607d;background-color:white;"><a href="https://www.neulandlabs.com/en" data-outlook-id="213cdfd4-bdcc-4bc2-bf1d-2e47d0292769" title="https://www.neulandlabs.com/en" style="color:#96607d;margin-top:0px;margin-bottom:0px;"><span style="text-decoration:underline;">Neuland Laboratories</span></a></span><span style="font-size:11pt;color:#373737;background-color:white;"> is accelerating its peptide manufacturing expansion, as<span> </span></span><span style="font-size:11pt;color:#000000;">the first of four scheduled modules has commenced operations at its commercial peptide manufacturing site. </span></div><div style="direction:ltr;text-align:justify;margin:0cm;font-family:Arial, sans-serif;font-size:11pt;color:#000000;">Significantly, with foundational infrastructure for the second module already in place, Neuland expects to begin work ahead of the original timeline once customer requirements are finalised — configuration, instrumentation and capacity are currently being defined in close collaboration with the customer whose projects will anchor the expanded capability.</div><div style="direction:ltr;text-align:justify;margin:0cm;font-family:Arial, sans-serif;"><span style="font-size:11pt;color:black;background-color:white;">The newly operational module one provides 7000L total reactor capacity, 750L of solid-phase peptide synthesis and 6250L liquid-phase peptide synthesis. This<span> </span></span><span style="font-size:11pt;color:#000000;">enables flexible customer programmes from</span><span style="font-size:11pt;color:black;background-color:white;"> small‑scale to multikilogram<span> </span></span><span style="font-size:12pt;color:#000000;">quantities</span><span style="font-size:11pt;color:black;background-color:white;"> for complete peptide APIs – including complex and long‑chain peptides – as well as commercial scale production of crude peptides. Additionally, the SPPS and LPPS reactors are housed in different suites enabling parallel operation and are supported by three DAC columns [one 45 cm and two 60 cm] and two lyophilisers with 100 L and 200 L capacities. </span></div><div style="direction:ltr;text-align:justify;margin:0cm;font-family:Arial, sans-serif;font-size:11pt;color:black;"><span style="background-color:white;"> </span></div><div style="direction:ltr;text-align:justify;margin:0cm;font-family:Arial, sans-serif;font-size:11pt;"><span style="color:#000000;">Following the $30 million investment in module one, Neuland is aligning further investment for subsequent modules with new customer requirements.<span> </span></span><span style="color:black;background-color:white;">Module two is planned to provide an overall reactor capacity of up to 18,000 L, comprising three 5,000 L LPPS reactors, as well as either a 1,000 L or 2,000 L SPPS reactor, and smaller reactors of up to the 1,000 L scale. This flexible configuration will allow Neuland to support a broad range of peptide programmes and production scales.</span></div><div style="direction:ltr;text-align:justify;margin:0cm;font-family:Arial, sans-serif;font-size:11pt;color:black;"><span style="background-color:white;"> </span></div><div style="direction:ltr;text-align:justify;margin:0cm;font-family:Arial, sans-serif;font-size:11pt;"><span style="color:black;">The range of partner indications</span><span style="color:#000000;"> is also broadening beyond obesity and metabolic disease, with oncology emerging<span> </span></span><span style="color:black;">as a particularly active area of early-stage development. As peptide pipelines expand,<span> </span></span><span style="color:#000000;">a growing number of biotech companies are struggling to access capable outsourced development and commercial manufacturing capacity.</span></div><div style="direction:ltr;text-align:justify;margin:0cm;font-family:Arial, sans-serif;font-size:11pt;"><span style="color:black;background-color:white;">Looking to the medium term,</span><span style="color:#000000;"> Neuland is already exploring options to meet future demand. Saharsh Davuluri, Neuland CEO & MD, added</span><span style="color:black;">:<span> </span><em>“</em></span><span style="color:#000000;"><em>Our goal is to ensure we have the capacity to meet customer demand not just over the next 24 months, but over the next decade, as we deepen our strategic partnerships with leading pharma and biotech companies.</em></span></div><div style="direction:ltr;text-align:justify;margin:0cm;font-family:Arial, sans-serif;font-size:11pt;color:#000000;"><em></em></div><div style="direction:ltr;background-color:white;margin:0cm;font-family:Arial, sans-serif;font-size:11pt;color:black;">Module one is supported by a team of nearly 212 peptide experts and this latest news follows on from an impressive few years for the CDMO. Revenues rose by a massive 116.3%<sup><a name="_ftnref1" data-outlook-id="43fedf66-f86c-45e2-b332-719a444d140c" title="" style="color:black;margin-top:0px;margin-bottom:0px;">1</a></sup> in its most recent quarterly results, driven chiefly by increased commercial contracts, as well as a growing number of clinical projects. </div><div style="direction:ltr;margin:0cm;font-family:Arial, sans-serif;font-size:10pt;"><span style="color:#96607d;"><sup><a name="_ftn1" data-outlook-id="060757e3-5955-40f3-b285-d181e9801318" title="" style="color:#96607d;margin-top:0px;margin-bottom:0px;">1</a></sup></span><span style="color:#000000;"> </span><span style="color:#96607d;"><a href="https://chemicals.economictimes.indiatimes.com/news/specialty-chemicals/neuland-laboratories-gains-after-robust-quarterly-surge-and-fresh-capacity-bets/133031202" data-outlook-id="d795d52b-67cd-4db5-bad4-5ca03c4dd894" title="https://chemicals.economictimes.indiatimes.com/news/specialty-chemicals/neuland-laboratories-gains-after-robust-quarterly-surge-and-fresh-capacity-bets/133031202" style="color:#96607d;margin-top:0px;margin-bottom:0px;"><span style="text-decoration:underline;">https://chemicals.economictimes.indiatimes.com/news/specialty-chemicals/neuland-laboratories-gains-after-robust-quarterly-surge-and-fresh-capacity-bets/133031202</span></a></span></div><div style="direction:ltr;text-align:justify;background-color:white;margin:0cm;font-family:Arial, sans-serif;font-size:10pt;color:black;"><strong></strong></div><div style="direction:ltr;text-align:center;background-color:white;margin:0cm;font-family:Arial, sans-serif;font-size:11pt;color:black;"><strong>-ENDS-</strong></div><div style="direction:ltr;text-align:center;background-color:white;margin:0cm;font-family:Arial, sans-serif;font-size:11pt;color:black;"><strong></strong></div><div style="direction:ltr;text-align:center;background-color:white;margin:0cm;font-family:Arial, sans-serif;font-size:11pt;color:black;"><strong></strong></div><div style="direction:ltr;text-align:justify;background-color:white;margin:0cm;font-family:Arial, sans-serif;font-size:10pt;color:black;"><em>Notes to editors</em></div><div style="direction:ltr;text-align:justify;background-color:white;margin:0cm;font-family:Arial, sans-serif;font-size:10pt;color:black;"><em></em></div><div style="direction:ltr;text-align:justify;background-color:white;margin:0cm;font-family:Arial, sans-serif;font-size:10pt;color:black;"><strong>About Neuland Labs</strong></div><div style="direction:ltr;text-align:justify;background-color:white;margin:0cm;font-family:Arial, sans-serif;font-size:10pt;color:black;">Neuland Laboratories Limited [Neuland] is a specialist API CDMO partner for big pharma and biotech – delivering world-class process development and commercial supply services for the most complex molecules and New Chemical Entities. Serving clients in over 80 countries, Neuland operates three US FDA and EU GMP-compliant facilities in India, with a combined reactor capacity of approximately 1218kL. The CDMO invested in a new commercial scale peptide facility in 2026, and is opening a large, dedicated R&D process development centre in Hyderabad.</div><div style="direction:ltr;text-align:justify;margin:0cm 0cm 8pt;font-family:Arial, sans-serif;font-size:10pt;color:black;"><span style="background-color:white;">Neuland is listed on the NSE (NEULANDLAB) and BSE (524558) in India. The company has filed over 1000 DMFs globally – as it also supports generic drug substance providers – and offers more than 100 APIs across multiple therapeutic areas</span></div><div style="direction:ltr;text-align:justify;margin:0cm 0cm 8pt;font-family:Arial, sans-serif;font-size:10pt;color:black;"><strong>Media Contacts</strong></div><div style="direction:ltr;text-align:justify;margin:0cm 0cm 8pt;font-family:Arial, sans-serif;font-size:10pt;color:black;">Nidhi Narain and Abdul Khalifeh</div><div style="direction:ltr;text-align:justify;margin:0cm 0cm 8pt;font-family:Arial, sans-serif;font-size:10pt;color:black;">De Facto Communications</div><div style="direction:ltr;text-align:justify;margin:0cm 0cm 8pt;font-family:Arial, sans-serif;font-size:10pt;color:#0078d4;"><a href="mailto:n.narain@defacto.co.uk" data-outlook-id="0bc6d5a0-dc4d-472d-a42a-7f53d0d05568" title="mailto:n.narain@defacto.co.uk" style="color:#0078d4;margin-top:0px;margin-bottom:0px;"><span style="text-decoration:underline;">n.narain@defacto.co.uk</span></a></div><div style="direction:ltr;text-align:justify;margin:0cm 0cm 8pt;font-family:Arial, sans-serif;font-size:10pt;color:#0563c1;"><a href="mailto:a.khalifeh@defacto.co.uk" data-outlook-id="7c08f463-36e2-4f0e-9018-c17f1a816109" title="mailto:a.khalifeh@defacto.co.uk" style="color:#0563c1;margin-top:0px;margin-bottom:0px;"><span style="text-decoration:underline;">a.khalifeh@defacto.co.uk</span></a></div></div></div></div></div></div></div></div></div></div>